A viewpoint on drugs that prolong the QTc interval

Area of Science:

• Cardiology
• Pharmacology
• Clinical Risk Assessment

Background:

• The clinical benefit of prolonging the QT interval corrected for heart rate (QTc) is not well-established.
• QTc prolongation induced by pharmacologic agents is generally considered a risk, except in critical scenarios.

Purpose of the Study:

• To evaluate the significance of QTc prolongation as a risk marker for drug-induced torsades de pointes.
• To emphasize the importance of assessing drug dosage in relation to QTc interval effects.

Main Methods:

• Review of existing evidence on QTc prolongation and its association with torsades de pointes.
• Analysis of the relationship between drug dosage and QTc interval changes.
• Conceptual framework for risk-benefit assessment based on QTc prolongation.

Main Results:

• Insufficient evidence supports the benefit of QTc prolongation.
• QTc prolongation is identified as a marker of risk for torsades de pointes.
• Dose-response assessment is crucial for determining if therapeutic benefits outweigh QTc prolongation risks.

Conclusions:

• QTc prolongation from medications should be viewed as a risk, particularly outside life-threatening situations.
• Establishing a clear dose-response relationship is vital for safe drug development and use.
• A wide safety margin, indicated by the separation of therapeutic and QTc-prolonging doses, is ideal.